Artemis Investment Management LLP Sells 34,122 Shares of Stryker Corporation $SYK

Key Points

• Artemis Investment Management LLP cut its stake in Stryker by 25.1% in Q4, selling 34,122 shares and leaving it with 101,908 shares valued at about $35.82 million.
• Director Ronda E. Stryker sold 250,000 shares at an average price of $362.92 (≈$90.73 million), reducing her ownership by 9.23%.
• Stryker missed Q1 estimates (EPS $2.60 vs. $2.98 expected; revenue $6.02B vs. $6.34B) citing a cyber incident, but management maintained FY‑2026 guidance of $14.90–$15.10 EPS even as several analysts trimmed price targets (consensus target ≈$401.43).

Artemis Investment Management LLP reduced its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 25.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 101,908 shares of the medical technology company's stock after selling 34,122 shares during the quarter. Artemis Investment Management LLP's holdings in Stryker were worth $35,818,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. United Financial Planning Group LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $27,000. Strive Asset Management LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $34,000. Copia Wealth Management boosted its holdings in shares of Stryker by 181.6% in the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock valued at $40,000 after buying an additional 69 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.60% of the company's stock.

Stryker Stock Performance

NYSE:SYK opened at $295.43 on Friday. The stock's 50-day moving average is $345.67 and its 200-day moving average is $356.95. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock has a market cap of $113.15 billion, a P/E ratio of 35.17, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92. Stryker Corporation has a 1-year low of $294.55 and a 1-year high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.74% and a net margin of 13.20%.Stryker's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.91 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker's payout ratio is 41.90%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Analysts Set New Price Targets

Several equities research analysts have recently commented on SYK shares. BTIG Research cut their price objective on Stryker from $397.00 to $379.00 and set a "buy" rating for the company in a report on Friday. Wells Fargo & Company cut their price target on Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a report on Friday. Raymond James Financial raised Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price target for the company in a report on Tuesday, January 6th. Truist Financial cut their price target on Stryker from $395.00 to $380.00 and set a "hold" rating for the company in a report on Wednesday, April 15th. Finally, Leerink Partners assumed coverage on Stryker in a report on Monday, April 13th. They set an "outperform" rating and a $410.00 price target for the company. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $401.43.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.